Improvements in Serum 25(OH)D Following Stoss Dosing in People With Cystic Fibrosis and Variable Adherence to Maintenance Regimens: A Retrospective Chart Review

Katelyn Gordon; Cole G. Chapman; Nichole M. Harklau; Katie Larson Ode; Brittany A. Wright

doi:10.1002/hsr2.71142

Back

Improvements in Serum 25(OH)D Following Stoss Dosing in People With Cystic Fibrosis and Variable Adherence to Maintenance Regimens: A Retrospective Chart Review

Journal article

Open access

Peer reviewed

Improvements in Serum 25(OH)D Following Stoss Dosing in People With Cystic Fibrosis and Variable Adherence to Maintenance Regimens: A Retrospective Chart Review

Katelyn Gordon, Cole G. Chapman, Nichole M. Harklau, Katie Larson Ode and Brittany A. Wright

Health science reports, Vol.8(8), e71142

08/2025

DOI: 10.1002/hsr2.71142

PMCID: PMC12322582

PMID: 40766771

Files and links (1)

url

https://doi.org/10.1002/hsr2.71142View

Published (Version of record) Open Access

Abstract

Background and Aims People with cystic fibrosis (pwCF) often have vitamin D deficiency and require vitamin D supplementation. The primary objective of this study was to evaluate the impact of ultrahigh dose cholecalciferol (“stoss dosing”) in pwCF with variable adherence to maintenance cholecalciferol. Methods Retrospective cohort study of pwCF who received initial stoss dose per protocol between January 2017 and November 2021 at University of Iowa Health Care adult and pediatric CF centers. Serum 25(OH)D concentrations were extracted from the EMR. The increase in serum 25(OH)D concentration associated with receiving stoss doses was evaluated using a longitudinal linear mixed effects regression model. Results Fifty-eight patients were included in the final analysis. The mean baseline 25(OH)D concentration before stoss therapy was 20.1 ng/mL (standard deviation [SD] = 5.9). The mean serum 25(OH)D concentration following stoss therapy increased to 27.9 ng/mL (SD = 7.5) and was measured on average 116 days after stoss administration. For patients with self-reported non-adherence to vitamin regimens, 16 out of 20 (80%) achieved a serum 25(OH)D concentration of at least 30 ng/mL after stoss therapy. Conclusions Our findings suggest that stoss dosing was associated with increased serum 25(OH)D concentrations. This benefit also existed for individuals with self-reported non-adherence to maintenance cholecalciferol regimens with most patients reaching concentration goals.

cystic fibrosis, vitamin D, quality improvement

stoss dosing

ultra high dose vitamin D supplementation

vitamin absorption

Details

Title: Subtitle: Improvements in Serum 25(OH)D Following Stoss Dosing in People With Cystic Fibrosis and Variable Adherence to Maintenance Regimens: A Retrospective Chart Review
Creators: Katelyn Gordon - University of Iowa Hospitals and Clinics
Cole G. Chapman - University of Iowa
Nichole M. Harklau - University of Iowa Hospitals and Clinics
Katie Larson Ode - University of Iowa
Brittany A. Wright - University of Iowa Hospitals and Clinics
Resource Type: Journal article
Publication Details: Health science reports, Vol.8(8), e71142
DOI: 10.1002/hsr2.71142
PMID: 40766771
PMCID: PMC12322582
NLM abbreviation: Health Sci Rep
ISSN: 2398-8835
eISSN: 2398-8835
Publisher: WILEY
Grant note: The authors received no specific funding for this work.
All authors have read and approved the final version of the manuscript. Dr. Wright had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. The authors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted.
Language: English
Date published: 08/2025
Academic Unit: Endocrinology and Diabetes; Stead Family Department of Pediatrics; Pharmacy Practice and Science
Record Identifier: 9984945082402771

Metrics

8 Record Views